Global Oncology Drugs Market 2021

January 2022 | 13 pages | ID: G5967CB5C192EN
StrategyHelix Inc

Abstracts

Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Today, millions of people are living with cancer or have had cancer. Cancer is the second leading cause of death in the United States. According to a report by StrategyHelix, the global oncology drugs market is set to increase by US$ 77,330 million during 2021-2027, growing at a CAGR of 7.4% during the forecast period. Rising geriatric population, surge in prevalence of cancer, early screening of the cancer, and increase in R&D spending from pharmaceutical & biotechnology companies are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for oncology drugs. The global oncology drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the global oncology drugs market has been segmented into chemotherapy, hormone therapy, immunotherapy, targeted therapy. The immunotherapy segment held the largest revenue share in 2020. By indication, the global oncology drugs market has been segmented into breast cancer, colorectal cancer, lung cancer, multiple myeloma, non-hodgkin’s lymphoma, prostate cancer, others. Among these, the lung cancer segment was accounted for the highest revenue generator in 2020. Geographically, the global oncology drugs market is segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global oncology drugs market is highly competitive. The oncology drugs market is dominated by key players, which are AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol Myers Squibb (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson and Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd.

Report Scope
Drug class: chemotherapy, hormone therapy, immunotherapy, targeted therapy
Indication: breast cancer, colorectal cancer, lung cancer, multiple myeloma, non-hodgkin’s lymphoma, prostate cancer, others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global oncology drugs market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. ONCOLOGY DRUGS MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY DRUG CLASS

Chemotherapy
Hormone therapy
Immunotherapy
Targeted therapy

PART 4. MARKET BREAKDOWN BY INDICATION

Breast cancer
Colorectal cancer
Lung cancer
Multiple myeloma
Non-hodgkin’s lymphoma
Prostate cancer
Others

PART 5. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 6. KEY COMPANIES

AbbVie Inc.
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bristol Myers Squibb (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche AG
Johnson and Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Takeda Pharmaceutical Co., Ltd.
About StrategyHelix
Disclaimer